NIH-funded research U01 cooperative agreement

Cord blood DNA marks linked to early-onset pediatric atopic dermatitis

Official title: The impact of the cord blood methylome on early-onset pediatric atopic dermatitis

Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-11365750 · Data updated 2026-11-12

A study will look at cord blood DNA methylation to find early clues for kids who develop atopic dermatitis and related allergies.

More Atopic Dermatitis research and trials

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionHenry Ford Health + Michigan State University Health Sciences
NIH-funded
Lab location1 site (East Lansing, United States)
Project startJune 24, 2026
Project endMay 31, 2031
Funding year2026
Award (this year)$784,314
NIH project number1U01AI182151-01A1
Project IDNIH-11365750 on NIH RePORTER

Who could benefit from this research

Could help

Newborns and children up to 11 years old, with a focus on those at heightened risk for atopic dermatitis and allergies, and their families.

Less likely to help

Children without the identified epigenetic risk patterns may not receive a benefit from this specific biomarker approach.

What this research studies

This project follows newborns from diverse communities to see if DNA methylation patterns in cord blood predict early atopic dermatitis and later allergies. It will use genome-wide DNA methylation sequencing to identify signals and validate them across several birth cohorts. The goal is to connect epigenetic marks at birth with disease risk, alongside genetic and environmental factors, to enable earlier prevention strategies. The study builds on a previously developed cord blood methylation score that distinguished early-onset AD, aiming to confirm and extend these findings in newborns.

Why it matters

Potential benefit: If successful, the research could lead to early identification of children at higher risk for atopic dermatitis and related allergic diseases, enabling earlier prevention efforts and personalized care.

How similar studies have gone: Previous work showed a cord blood methylation signature that could differentiate early-onset AD with high accuracy.

Where this research is happening

  • Henry Ford Health + Michigan State University Health Sciences
    East Lansing, United States
    Active

Researchers

  • Principal investigator: Eapen, Amy — Henry Ford Health + Michigan State University Health Sciences
  • Study coordinator: Eapen, Amy

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.